Medytox Inc.

Samsung Display Co., Ltd.

Samsung Electronics Co., Ltd.

Hyun Ho Jung

Gi Hyeok Yang

Chang Hoon Rhee

Hack Woo Kim

Hee Seong Jeong

Hyun Jee Kim

Sun Hwa Kim

Hee Dong Woo

Jae Hong Kim

Sang Min Hong

Hyang Yul Kim

Hyun Gue Song

Junho Lee

Jin Won Lee

Cheol Jin Kim

Jeong Yun Lee

Geum Jung Seong

Seung Soo Hong

Hyo Min Kim

Dong Kwon Kim

Sung Bum Kim

Seung Hwan Baek

Sujin Cho

Jun Ho Lee

Chul Hyun Choi

Jeong Yeon Seo

Gi Hyuck Ryu

Cheon Soo Lim

Dong Kyu Lee

Hyung Pyo Hong

Young Rae Lee

Jung Hyun Song

Joon Chan Kong

The invention relates to the use of an animal-protein-free botulinum toxin composition to treat a disease, disorder or condition in a patient in need thereof whereby the animal-protein-free botulinum toxin composition exhibits a longer lasting effect in the patient compared to an animal-protein-containing botulinum toxin composition.

Long lasting effect of new botulinum toxin formulations

A semiconductor device is provided. The semiconductor device includes a substrate, a first active pattern, which extends in a first direction on the substrate, a second active pattern, which extends in the first direction on the substrate and is spaced apart from the first active pattern by a first pitch in a second direction different from the first horizontal direction, a third active pattern, which extends in the first direction on the substrate and is spaced apart from the second active pattern by a second pitch greater than the first pitch in the second direction, a field insulating layer, which borders side walls of each of the first to third active patterns, a dam, which is between the first active pattern and the second active pattern on the field insulating layer, the region between the second active pattern and the third active pattern being free of the dam, a gate electrode, which extends in the second direction, and has a first portion on the first active pattern, a second portion on the second active pattern, and a third portion on the third active pattern, a first work function layer between the first portion of the gate electrode and the dam, and a second work function layer between the second portion of the gate electrode and the dam.

Semiconductor device

A display device includes: a substrate; a display element on the substrate; a capping layer on the display element; a first auxiliary layer on the capping layer; and a thin-film encapsulation layer on the first auxiliary layer, wherein the thin-film encapsulation layer comprises a (1-1)-th inorganic encapsulation layer on the first auxiliary layer and a (1-2)-th inorganic encapsulation layer on the (1-1)-th inorganic encapsulation layer, wherein a refractive index of the first auxiliary layer is smaller than a refractive index of the capping layer and a refractive index of the (1-1)-th inorganic encapsulation layer, and a refractive index of the (1-2)-th inorganic encapsulation layer is smaller than the refractive index of the (1-1)-th inorganic encapsulation layer.

Display device

A semiconductor device includes: a substrate; an active pattern and a field insulating layer surrounding a sidewall of the active pattern on the substrate; first and second gate electrodes on the active pattern and extending in a direction different from that of the active pattern; an interlayer insulating layer surrounding a sidewall of each of the first and second gate electrodes; a gate spacer on opposing sidewalls of each of the first and second gate electrodes that includes a first sidewall and a second sidewall opposite the first sidewall in the first horizontal direction, each of which contacts the interlayer insulating layer; and a first gate cut dividing the second gate electrode into two portions, wherein the first gate cut includes a same material as the gate spacer; and wherein a first width of the first gate cut is smaller than a second width of the gate spacer.

Semiconductor devices

Disclosed herein is a liquid pharmaceutical composition of botulinum toxin which is improved in stability. It comprises botulinum toxin, polysorbate, and methionine and optionally isoleucine. The liquid pharmaceutical composition eliminates the risk of contaminating the body with serum-derived pathogens or microorganisms and can be administered safely to the body. Also, the composition is convenient for use as a direct injection for patients, has good storage stability of botulinum toxin at 25˜37° C., as well as at refrigerated temperatures.

Pharmaceutical liquid composition of botulinum toxin with improved stability

A display device includes a display panel; and a light path control member disposed on the display panel, wherein the light path control member includes: a housing including a plurality of partition walls and a channel defined between two adjacent partition walls among the plurality of partition walls; a light absorbing solution configured to block transmission of light; and a first fluid transfer portion configured to control flowing of the light absorbing solution into and out of the channel.

A display device includes: a substrate; a display element on the substrate; a capping layer on the display element; an optical layer on the capping layer, and including: a first optical layer on the display element; and a second optical layer on the first optical layer; and a thin film encapsulation layer on the optical layer, and including: a first inorganic encapsulation layer on the second optical layer; an auxiliary layer on the first inorganic encapsulation layer; an organic encapsulation layer on the auxiliary layer; and a second inorganic encapsulation layer on the organic encapsulation layer. A refractive index of the second optical layer is smaller than a refractive index of the capping layer, and a refractive index of the first optical layer is between the refractive index of the second optical layer and the refractive index of the capping layer.

A semiconductor device including a plurality of active regions extending in a first direction on a substrate; a device isolation layer between the plurality of active regions such that upper portions of the plurality of active regions protrude from the device isolation layer; a first gate electrode and a second gate electrode extending in a second direction crossing the first direction and intersecting the plurality of active regions, respectively, on the substrate, the first gate electrode being spaced apart from the second gate electrode in the second direction; a first gate separation layer between the first gate electrode and the second gate electrode; and a second gate separation layer under the first gate separation layer and between the first gate electrode and the second gate electrode, the second gate separation layer extending into the device isolation layer in a third direction crossing the first direction and the second direction.

Method of manufacturing a semiconductor device

A display device includes a light control film including a first alignment pattern. The display device further includes a display panel including a second alignment pattern. The first alignment pattern and the second alignment pattern are at least partially overlapped with one another.

Light control film and display device comprising the same

A light control panel includes: a first substrate; a light control layer that includes first light blocking parts and second light blocking parts that are disposed on the first substrate, extend along a first direction, and are spaced apart from each other along a second direction that crosses the first direction; and a second substrate disposed on the light control layer. The first light blocking parts and the second light blocking part are alternately arranged along the second direction. A first width of each of the first light blocking parts in the second direction and a second width of each of the second light blocking parts in the second direction differ from each other.

Light control panel and display device including 1HE same

The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-lysing concentration of one or more of cholate and chenodeoxycholate in a pharmaceutically acceptable formulation to the subject in need thereof.

Methods and compositions of bile acids and salts for reduction of fat

Growing community of inventors

Seoul, South Korea

Hyun Ho Jung